Axiogenesis Cor.At mESC cardiomyocytes

Monday, 21 June, 2010 | Supplied by: Capsugel Australia Pty Ltd

Axiogenesis Cor.At mESC cardiomyocytes

Embryonic stem cell-derived cardiomyocytes have many of the phenotypic properties of primary cardiomyocytes and show great potential to model human diseases. The Cor.At cells are cardiomyocytes derived from transgenic mouse embryonic stem cells and are available cryopreserved in ampoules.

The cells are highly pure with ampoules containing 99% cardiomyocytes. Their minimal lot-to-lot variation is claimed to give consistent performance and the standardised production process ensures stable supply.

The cardiomyocytes are a good predictive model with relevant background including all important ion channels well characterised.

They are suitable for applications including: electrophysiology (patch clamp, microelectrode arrays, Ca2+ flux analysis), non-arrhythmic cardiotoxicity (cell viability, label-free analysis, troponin release), drug profiling and target discovery (hypertrophy, gene expression, transfection, tissue engineering).

Online: lonzabioscience.com.au
Phone: 1300 657508
Related Products

Biosensis MAP2 antibodies

Biosensis's validated MAP2 antibodies are designed to help users identify MAP2, whether they...

Bio-Rad Laboratories Celselect Slides validated antibodies for rare cell and CTC enumeration

The antibodies are specific to CTC surface markers to enable the sensitive and specific...

Microbiologics UV-BioTAG QC microorganisms for quality control testing

UV-BioTAG, a line of reference strains containing green fluorescent protein (GFP) markers, makes...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd